scholarly journals Differences in breast cancer treatment pathways for women participating in screening through BreastScreen New South Wales

2020 ◽  
Vol 13 (6) ◽  
Author(s):  
Zahra Shahabi-Kargar ◽  
Amy Johnston ◽  
Matthew Warner-Smith ◽  
Nicola Creighton ◽  
David Roder
2017 ◽  
Vol 166 (3) ◽  
pp. 843-854 ◽  
Author(s):  
Gemma Jacklyn ◽  
Kevin McGeechan ◽  
Les Irwig ◽  
Nehmat Houssami ◽  
Stephen Morrell ◽  
...  

2020 ◽  
Author(s):  
Qing Yang ◽  
Ting Luo ◽  
Wei Zhang ◽  
Xiaorong Zhong ◽  
Ping He ◽  
...  

Abstract Background: Due to the multidimensional, multilayered, and chronological order of the cancer data in this study, it was challenging for us to extract treatment paths. Therefore, it was necessary to design a new data mining scheme to effectively extract the treatment path of breast cancer. To determine whether the cSPADE algorithm and system clustering proposed in this study can effectively identify the treatment pathways for early breast cancer. Methods: We applied data mining technology to the electronic medical records of 6891 early breast cancer patients to mine treatment pathways. We provided a method of extracting data from EMR and performed three-stage mining: determining the treatment stage through the cSPADE algorithm → system clustering for treatment plan extraction → cSPADE mining sequence pattern for treatment. The Kolmogorov-Smirnov test and correlation analysis were used to cross-validate the sequence rules of early breast cancer treatment pathways.Results: We unearthed 55 sequence rules for early breast cancer treatment, 3 preoperative neoadjuvant chemotherapy regimens, 3 postoperative chemotherapy regimens, and 2 chemotherapy regimens for patients without surgery. Through 5-fold cross-validation, Pearson and Spearman correlation tests were performed. At the significance level of P <0.05, all correlation coefficients of support, confidence and lift were greater than 0.89. Using the Kolmogorov-Smirnov test, we found no significant differences between the sequence distributions.Conclusions: The cSPADE algorithm combined with system clustering can achieve hierarchical and vertical mining of breast cancer treatment models. By uncovering the treatment pathways of early breast cancer patients by this method, the real-world breast cancer treatment behavior model can be evaluated, and it can provide a reference for the redesign and optimization of the treatment pathways.


1997 ◽  
Vol 67 (1) ◽  
pp. 9-14 ◽  
Author(s):  
Pamela Adelson ◽  
Kim Lim ◽  
Tim Churches ◽  
Ru Nguyen

Pathology ◽  
1995 ◽  
Vol 27 (4) ◽  
pp. 306-311 ◽  
Author(s):  
Michael Bilous ◽  
Margaret McCredie ◽  
Lesley Porter

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 17043-17043
Author(s):  
C. K. Lee ◽  
L. Browne ◽  
P. Bastick ◽  
W. Liauw

17043 Background: Ethnicity may influence both the incidence and prognosis of breast cancer. We have conducted an analysis to determine if women from non-English speaking backgrounds (NESB) living in New South Wales (NSW), Australia, present with later stage breast cancer compared to women from English speaking backgrounds (ESB); and to determine whether there is an impact on their survival. Methods: Data from the NSW Cancer Registry (1980 to 2004) was used to identify women with their first presentation of breast cancer. Stage of breast cancer was classified as early (insitu or localized) versus late (regional nodal or distant metastatic spread) according to registry definitions. Country of birth was used as a surrogate for language status. Stage at diagnosis was compared between ESB versus NESB women. Logistic regression was used to determine the odds of late stage disease and Cox regression to determine survival outcomes Results: 60,676 of 75,583 cases were considered suitable for analysis. Of these 16.64% were NESB. Accounting for potential confounding variables, NESB women were more likely to have late stage disease than ESB women (OR= 1.12; 95% CI, 1.07 to 1.17). Analysis by geographical region of birth revealed women born in Middle Eastern region were most likely to have late stage disease at presentation (OR 1.41; 95% CI, 1.25 to 1.60). In multivariable analysis of all-cause mortality NESB women had a superior overall survival (HR 0.90; 95% CI 0.87 to 0.94) compared to ESB women, however, there was no difference in breast cancer specific survival between these groups by univariate analysis (logrank p=0.46). Conclusions: In New South Wales, Australia, NESB women have a delayed presentation with breast cancer as indicted by more advanced stage. However, stage-adjusted, breast cancer specific survival in NESB women is similar to the ESB women. Further studies are required to determine the reasons for delayed detection for NESB women. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document